Armata AP-SA02 shows promise for SAB in Phase IIa trial, underscoring growing potential of phage… EP News Bureau Oct 30, 2025 Phase IIa data show faster infection resolution and shorter hospital stays when AP-SA02 is added to standard antibiotic therapy,…
Prioritised investments from pharma companies shaping competitive pipeline landscape of… GlobalData Jul 11, 2024 In recent years, bronchiectasis has garnered a significant amount of attention, with pharmaceutical companies prioritising their…
